Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
=======================================================================================================================================

* Paul Nghiem
* Shailender Bhatia
* Evan J Lipson
* William H Sharfman
* Ragini R Kudchadkar
* Andrew S Brohl
* Philip A Friedlander
* Adil Daud
* Harriet M Kluger
* Sunil A Reddy
* Brian C Boulmay
* Adam Riker
* Melissa A Burgess
* Brent A Hanks
* Thomas Olencki
* Kari Kendra
* Candice Church
* Tomoko Akaike
* Nirasha Ramchurren
* Michi M Shinohara
* Bob Salim
* Janis M Taube
* Erin Jensen
* Mizuho Kalabis
* Steven P Fling
* Blanca Homet Moreno
* Elad Sharon
* Martin A Cheever
* Suzanne L Topalian